Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Astrazeneca

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Astrazeneca

1 Apr 2019 18:00

RNS Number : 7122U
FTSE Russell
01 April 2019
 

 

 

 

 

AstraZeneca (UK): Shares in Issue ChangeChanges in FTSE UK Index Series

01 April 2019

Following the receipt of updated shares in issue information for AstraZeneca (UK, constituent) as a result of a primary placing, please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

04 April 2019

FTSE 350 Index

04 April 2019

FTSE All-Share Index

04 April 2019

FTSE 350 Higher Yield Index

04 April 2019

Techmark All Share Index

04 April 2019

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSSSDFDFFUSEEL
8910111213141516
Date   Source Headline
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU
26th Jan 20213:00 pmRNSBlock listing application
26th Jan 20217:00 amRNSSymbicort approved in China for mild asthma
25th Jan 20217:05 amRNSCalquence approved in Japan for CLL
25th Jan 20217:00 amRNSCalquence met primary endpoint against ibrutinib
20th Jan 20217:00 amRNSEnhertu approved in the EU for breast cancer
18th Jan 20217:00 amRNSEnhertu approved in the US for gastric cancer
15th Jan 20217:00 amRNSImfinzi new dosing approved in EU
6th Jan 20217:00 amRNSFarxiga granted US Priority Review for CKD
4th Jan 20213:00 pmRNSTotal Voting Rights
4th Jan 20217:00 amRNSAtacand divestment in over 70 countries completed
30th Dec 20207:00 amRNSAstraZeneca’s COVID-19 vaccine authorised in UK
29th Dec 20207:00 amRNSLynparza approved in Japan for three cancers
21st Dec 20207:05 amRNSTagrisso approved in the US for early lung cancer
21st Dec 20207:00 amRNSUpdate on US regulatory review of roxadustat
17th Dec 20204:00 pmRNSDirector/PDMR Shareholding
16th Dec 20206:15 pmRNSDirector/PDMR Shareholding
15th Dec 20207:00 amRNSImfinzi new dose receives positive EU CHMP opinion
14th Dec 20207:05 amRNSTrastuzumab deruxtecan positive CHMP
14th Dec 20207:00 amRNSTrixeo Aerosphere approved in the EU for COPD
14th Dec 20207:00 amRNSAstraZeneca to acquire Alexion Pharmaceuticals Inc
1st Dec 20203:00 pmRNSBlock listing Interim Review
1st Dec 20203:00 pmRNSTotal Voting Rights
1st Dec 20207:00 amRNSCrestor to be divested to Grünenthal in Europe
30th Nov 20207:00 amRNSForxiga approved in Japan for heart failure
23rd Nov 20207:00 amRNSAZD1222 vaccine effective against COVID-19
20th Nov 20207:00 amRNSImfinzi new dosing approved in the US
10th Nov 20207:00 amRNSTezepelumab Phase III trial met primary endpoint
9th Nov 20207:00 amRNSCalquence approved in the EU for CLL
6th Nov 20207:00 amRNSBrilinta approved in the US in stroke
5th Nov 20207:15 amRNSLynparza approved in the EU for wider ovarian use
5th Nov 20207:10 amRNSLynparza approved in the EU for prostate cancer
5th Nov 20207:05 amRNSForxiga approved in the EU for heart failure
5th Nov 20207:00 amRNSAZN: Year-to-date and Q3 2020 results
2nd Nov 20203:00 pmRNSTotal Voting Rights
30th Oct 20207:00 amRNSAtacand to be divested in more than 70 countries
29th Oct 20207:00 amRNSDirectorate Change
28th Oct 20207:03 amRNSEnhertu US Priority Review in gastric cancer
28th Oct 20207:00 amRNSForxiga CV outcomes benefit approved in China
20th Oct 20207:00 amRNSTagrisso adjuvant lung cancer US Priority Review
19th Oct 20207:00 amRNSForxiga HF receives positive CHMP opinion
19th Oct 20207:00 amRNSTrixeo Aerosphere receives positive CHMP opinion
12th Oct 20207:00 amRNSCOVID-19 antibodies advance and get US funding
2nd Oct 202011:19 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSFarxiga granted US BTD in chronic kidney disease
1st Oct 20203:00 pmRNSTotal Voting Rights
25th Sep 20207:00 amRNSDirectorate Change
8910111213141516

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
DDV1
DDV1.L
LSE
0.00%
ALAI
ALAI.L
LSE
0.00%
FAS
Fidelity Asian Values
LSE
-2.40%
CMOP
Inv Bbg Commod
LSE
-1.37%
SHRS
Shires Inc.
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
EZJ
easyJet
LSE
0.34%